Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT01611909




Registration number
NCT01611909
Ethics application status
Date submitted
29/05/2012
Date registered
5/06/2012
Date last updated
20/06/2012

Titles & IDs
Public title
Citriodiol® and Impetigo
Scientific title
A Randomised, Double-blinded, Pilot Study Investigating the Safety and Efficacy of Topical P-menthane-3,8-diol Oil Extract in the Treatment of Childhood Impetigo.
Secondary ID [1] 0 0
Citriodiol®&Impetigo-001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Impetigo 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - p-menthane-3,8-diol oil

Experimental: 2% PMDO -

Experimental: 5% PMDO -

Active Comparator: Mupirocin -


Treatment: Drugs: p-menthane-3,8-diol oil
Apply topically to affected area twice daily
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Improvement in severity score of impetigo
Timepoint [1] 0 0
2 weeks

Eligibility
Key inclusion criteria
- age between 12 months and 12 years

- dermatologist-confirmed impetigo

- written informed consent provided by parents
Minimum age
12 Months
Maximum age
12 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- impetigo requiring oral/systemic therapy

- diagnosis of another form of staphylococcal or streptococcal disease (eg, cellulitis,
erysipelas, abscess)

- serious local infection (eg, cellulitis, abscess, wound infection) or systemic
infection

- oral or topical antibiotics

- known allergy to topical insect repellents

- patients receiving systemic corticosteroids, immunosuppressive agents, radiation
therapy, chemotherapy within 1 month prior to entry into study

- history of any clinically significant or poorly controlled cardiac, haematologic,
hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, psychiatric, and/or
other major disease as determined by the investigator

- current enrollment in any other trial of an investigational drug within 30 days prior
to study drug administration

- other unspecified reasons, in the opinion of the investigator that makes the patient
unsuitable for enrollment.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Crossover
Other design features
Phase
Phase 2/Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Unknown status
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/07/2012
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/03/2013
Actual
Sample size
Target
30
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Royal North Shore Hospital - St Leonards
Recruitment postcode(s) [1] 0 0
2065 - St Leonards

Funding & Sponsors
Primary sponsor type
Other
Name
Royal North Shore Hospital
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study aims to investigate the efficacy and safety of topical p-menthane-3,8-diol
(PMD)-rich Corymbia Citriodora oil (Citriodiol®) in children with impetigo. Citriodiol® is
already known to be effective as an insect repellent and is safe in its topical application.
The investigators have also found in our laboratory that it is bactericidal against
Staphylococcus aureus, the bacteria responsible for causing impetigo. Parents are always
searching for a natural alternative to antibiotics (the current gold standard treatment for
impetigo), and the investigators believe Citriodiol® could provide this possible alternative.
Trial website
https://clinicaltrials.gov/ct2/show/NCT01611909
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Shreya Dixit, B Med Sci, MBBS (Hons)
Address 0 0
Country 0 0
Phone 0 0
(02) 9926 7111
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT01611909